ABNORMAL EXPRESSION OF THE CYSTEINE AND GLYCINE-RICH PROTEIN 2 GENE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
(Abstract release date: 05/19/16)
EHA Library. Wang S. 06/09/16; 132400; E851
Ms. Shu-Juan Wang
Contributions
Contributions
Abstract
Abstract: E851
Type: Eposter Presentation
Background
Cysteine and glycine-rich protein 2(CSRP2) is a member of the CSRP family of genes, encoding a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. It has been reported that determination of CSRP2 protein level had a significant meaning for cardiovascular and respiratory diseases. In view of the important function of CSRP2 in cell growth and differention, CSRP2 may also have a role in carcinogenesis. However, the expression of CSRP2 has not been explored in leukemia, especially in B-cell acute lymphoblastic leukemia (ALL).
Aims
The purpose of this study was to investigate the expression of human CSRP2 messenger RNA in B-cell acute lymphoblastic leukemia by real-time fluorescent quantitative reverse transcription-polymerase chain reaction assay.
Methods
A real-time quantitative RT-PCR based on TaqMan fluorescence methodology was used to quantify the CSRP2 mRNA copy number in the bone marrow cells from patients with leukemia and in 11 human leukemic cell lines. Normal marrow samples from the allogeneic stem cell transplantation donors were served as control. Informed consent was obtained for every marrow sample.
Results
Expression levels of the CSRP2 gene in leukemic cell lines, leukemia patients and normal donor marrow are shown in Figure 1. These results showed that the relative levels of CSRP2 gene expression in marrow from the 212 newly diagnosed B-cell ALL was significantly higher than those of marrow from the 43 healthy donors(p<0.01). No statistical significant difference was observed in 18 newly diagnosed T-cell ALL, 73 AML and 43 healthy donors (p’s > 0.05), but it was higher in SupB15, BV-173 cells from B-cell ALL cell lines than in other cells from AML or T-cell ALL cell lines. Focusing on B-cell ALL patients, the median level of CSRP2 in 212 newly diagnosed patients was 42.13%(range 0-740.55%), while the median level in 290 treated patients who achieved CR decreased to 0.55%(range 0-21.21%). However, in 17 refractory patients and 22 relapsed patients, the median level was 60.83%(range 2.89-548.47%) and 43.17%(range 0.08-346.81%), respectively. In newly diagnosed B-cell ALL, 8 patients with MLL-AF4 translocation showed higher CSRP2 expression levels compared with 124 patients without this translocation(p<0.01). Figure1.Expression levels of CSRP2 in leukemic cell lines, leukemia patients and normal donor marrow. HD denotes healthy donors; De nove denotes newly diagnosed; CR denotes complete remission; Horizontal lines represent median CSRP2 expression for each group.* indicates p<0.05 compared with HD; & indicates p<0.05 compared with De novo B-cell ALL; # indicates p<0.05 compared with CR B-cell ALL.
Conclusion
These findings suggest that abnormal expression of CSRP2 in leukemia may be involved in the pathomechanism of B-cell ALL.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Real time PCR
Type: Eposter Presentation
Background
Cysteine and glycine-rich protein 2(CSRP2) is a member of the CSRP family of genes, encoding a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. It has been reported that determination of CSRP2 protein level had a significant meaning for cardiovascular and respiratory diseases. In view of the important function of CSRP2 in cell growth and differention, CSRP2 may also have a role in carcinogenesis. However, the expression of CSRP2 has not been explored in leukemia, especially in B-cell acute lymphoblastic leukemia (ALL).
Aims
The purpose of this study was to investigate the expression of human CSRP2 messenger RNA in B-cell acute lymphoblastic leukemia by real-time fluorescent quantitative reverse transcription-polymerase chain reaction assay.
Methods
A real-time quantitative RT-PCR based on TaqMan fluorescence methodology was used to quantify the CSRP2 mRNA copy number in the bone marrow cells from patients with leukemia and in 11 human leukemic cell lines. Normal marrow samples from the allogeneic stem cell transplantation donors were served as control. Informed consent was obtained for every marrow sample.
Results
Expression levels of the CSRP2 gene in leukemic cell lines, leukemia patients and normal donor marrow are shown in Figure 1. These results showed that the relative levels of CSRP2 gene expression in marrow from the 212 newly diagnosed B-cell ALL was significantly higher than those of marrow from the 43 healthy donors(p<0.01). No statistical significant difference was observed in 18 newly diagnosed T-cell ALL, 73 AML and 43 healthy donors (p’s > 0.05), but it was higher in SupB15, BV-173 cells from B-cell ALL cell lines than in other cells from AML or T-cell ALL cell lines. Focusing on B-cell ALL patients, the median level of CSRP2 in 212 newly diagnosed patients was 42.13%(range 0-740.55%), while the median level in 290 treated patients who achieved CR decreased to 0.55%(range 0-21.21%). However, in 17 refractory patients and 22 relapsed patients, the median level was 60.83%(range 2.89-548.47%) and 43.17%(range 0.08-346.81%), respectively. In newly diagnosed B-cell ALL, 8 patients with MLL-AF4 translocation showed higher CSRP2 expression levels compared with 124 patients without this translocation(p<0.01). Figure1.Expression levels of CSRP2 in leukemic cell lines, leukemia patients and normal donor marrow. HD denotes healthy donors; De nove denotes newly diagnosed; CR denotes complete remission; Horizontal lines represent median CSRP2 expression for each group.* indicates p<0.05 compared with HD; & indicates p<0.05 compared with De novo B-cell ALL; # indicates p<0.05 compared with CR B-cell ALL.
Conclusion
These findings suggest that abnormal expression of CSRP2 in leukemia may be involved in the pathomechanism of B-cell ALL.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Real time PCR
Abstract: E851
Type: Eposter Presentation
Background
Cysteine and glycine-rich protein 2(CSRP2) is a member of the CSRP family of genes, encoding a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. It has been reported that determination of CSRP2 protein level had a significant meaning for cardiovascular and respiratory diseases. In view of the important function of CSRP2 in cell growth and differention, CSRP2 may also have a role in carcinogenesis. However, the expression of CSRP2 has not been explored in leukemia, especially in B-cell acute lymphoblastic leukemia (ALL).
Aims
The purpose of this study was to investigate the expression of human CSRP2 messenger RNA in B-cell acute lymphoblastic leukemia by real-time fluorescent quantitative reverse transcription-polymerase chain reaction assay.
Methods
A real-time quantitative RT-PCR based on TaqMan fluorescence methodology was used to quantify the CSRP2 mRNA copy number in the bone marrow cells from patients with leukemia and in 11 human leukemic cell lines. Normal marrow samples from the allogeneic stem cell transplantation donors were served as control. Informed consent was obtained for every marrow sample.
Results
Expression levels of the CSRP2 gene in leukemic cell lines, leukemia patients and normal donor marrow are shown in Figure 1. These results showed that the relative levels of CSRP2 gene expression in marrow from the 212 newly diagnosed B-cell ALL was significantly higher than those of marrow from the 43 healthy donors(p<0.01). No statistical significant difference was observed in 18 newly diagnosed T-cell ALL, 73 AML and 43 healthy donors (p’s > 0.05), but it was higher in SupB15, BV-173 cells from B-cell ALL cell lines than in other cells from AML or T-cell ALL cell lines. Focusing on B-cell ALL patients, the median level of CSRP2 in 212 newly diagnosed patients was 42.13%(range 0-740.55%), while the median level in 290 treated patients who achieved CR decreased to 0.55%(range 0-21.21%). However, in 17 refractory patients and 22 relapsed patients, the median level was 60.83%(range 2.89-548.47%) and 43.17%(range 0.08-346.81%), respectively. In newly diagnosed B-cell ALL, 8 patients with MLL-AF4 translocation showed higher CSRP2 expression levels compared with 124 patients without this translocation(p<0.01). Figure1.Expression levels of CSRP2 in leukemic cell lines, leukemia patients and normal donor marrow. HD denotes healthy donors; De nove denotes newly diagnosed; CR denotes complete remission; Horizontal lines represent median CSRP2 expression for each group.* indicates p<0.05 compared with HD; & indicates p<0.05 compared with De novo B-cell ALL; # indicates p<0.05 compared with CR B-cell ALL.
Conclusion
These findings suggest that abnormal expression of CSRP2 in leukemia may be involved in the pathomechanism of B-cell ALL.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Real time PCR
Type: Eposter Presentation
Background
Cysteine and glycine-rich protein 2(CSRP2) is a member of the CSRP family of genes, encoding a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. It has been reported that determination of CSRP2 protein level had a significant meaning for cardiovascular and respiratory diseases. In view of the important function of CSRP2 in cell growth and differention, CSRP2 may also have a role in carcinogenesis. However, the expression of CSRP2 has not been explored in leukemia, especially in B-cell acute lymphoblastic leukemia (ALL).
Aims
The purpose of this study was to investigate the expression of human CSRP2 messenger RNA in B-cell acute lymphoblastic leukemia by real-time fluorescent quantitative reverse transcription-polymerase chain reaction assay.
Methods
A real-time quantitative RT-PCR based on TaqMan fluorescence methodology was used to quantify the CSRP2 mRNA copy number in the bone marrow cells from patients with leukemia and in 11 human leukemic cell lines. Normal marrow samples from the allogeneic stem cell transplantation donors were served as control. Informed consent was obtained for every marrow sample.
Results
Expression levels of the CSRP2 gene in leukemic cell lines, leukemia patients and normal donor marrow are shown in Figure 1. These results showed that the relative levels of CSRP2 gene expression in marrow from the 212 newly diagnosed B-cell ALL was significantly higher than those of marrow from the 43 healthy donors(p<0.01). No statistical significant difference was observed in 18 newly diagnosed T-cell ALL, 73 AML and 43 healthy donors (p’s > 0.05), but it was higher in SupB15, BV-173 cells from B-cell ALL cell lines than in other cells from AML or T-cell ALL cell lines. Focusing on B-cell ALL patients, the median level of CSRP2 in 212 newly diagnosed patients was 42.13%(range 0-740.55%), while the median level in 290 treated patients who achieved CR decreased to 0.55%(range 0-21.21%). However, in 17 refractory patients and 22 relapsed patients, the median level was 60.83%(range 2.89-548.47%) and 43.17%(range 0.08-346.81%), respectively. In newly diagnosed B-cell ALL, 8 patients with MLL-AF4 translocation showed higher CSRP2 expression levels compared with 124 patients without this translocation(p<0.01). Figure1.Expression levels of CSRP2 in leukemic cell lines, leukemia patients and normal donor marrow. HD denotes healthy donors; De nove denotes newly diagnosed; CR denotes complete remission; Horizontal lines represent median CSRP2 expression for each group.* indicates p<0.05 compared with HD; & indicates p<0.05 compared with De novo B-cell ALL; # indicates p<0.05 compared with CR B-cell ALL.
Conclusion
These findings suggest that abnormal expression of CSRP2 in leukemia may be involved in the pathomechanism of B-cell ALL.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Real time PCR
{{ help_message }}
{{filter}}